Table 1 Demographic and clinical characteristics of the study group
Successful CTO-PCI n = 32 | |
|---|---|
Age (y) | 59 ± 10.2 |
Female | 8 (21 %) |
Hypertension | 15 (47 %) |
Hyperlipidemia | 17 (53 %) |
Diabetes | 10 (31 %) |
HbA1C (%) | 7 ± 1.7 |
History of smoking | |
No | 13 (41 %) |
Yes | 11 (34 %) |
Current smoker | 8 (25 %) |
Creatinine (mg/dl) | 1 ± 0.2 |
GFR (MDRD-4; ml/min) | 58 ± 5.2 |
Previous stroke | 1 (3 %) |
Peripheral arterial vasculopathy | 8 (25 %) |
LVEF (%) by echocardiography | 30 ± 6.9 |
30 (25–35.8) | |
ACEF score* | 2 ± 0.8 |
2 (1.4–2.7) | |
Angina | 11 (34 %) |
NYHA functional class | |
1 | 0 |
2 | 23 (72 %) |
3 | 9 (28 %) |
Atrial fibrillation/Atrial flutter | 1 (3 %) |
Previous MI | 18 (56 %) |
Previous STEMI | 14 (44 %) |
Q waves | 19 (59 %) |
Previous PCI | 11 (34 %) |
Previous CABG | 4 (13 %) |
ACEi/ARB | 26 (81 %) |
Beta blockers | 29 (91 %) |
Aldosterone receptor antagonists | 14 (44 %) |
Diuretics | 16 (50 %) |
Digoxin | 1 (3 %) |
Statin | 30 (94 %) |